Research programme: anticancer therapeutics - EpiCept Corporation

Drug Profile

Research programme: anticancer therapeutics - EpiCept Corporation

Alternative Names: BCH 19746; BCH 23540; CV 2105; CV 58151; EPC 2105; EPC 58151; MX 116407; MX 2105; MX 58151

Latest Information Update: 17 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiCept Corporation
  • Class Nitriles
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Solid tumours

Most Recent Events

  • 17 Mar 2008 Discontinued - Preclinical for Cancer in USA (IV)
  • 17 Mar 2008 Discontinued - Preclinical for Solid tumours in Canada (IV)
  • 05 Oct 2006 EpiCept has filed an IND with the US FDA for EPC 2407 for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top